Search clinical trials for: CYP3A4 inhibitor

Total 68017 results

Daiichi Sankyo, Inc.

Completed

Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants

Pharmacokinetics

United States
Epizyme, Inc.

Completed

Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer

Solid Tumor | Mesothelioma | Rhabdoid Tumor | Hematologic Malignancy | Advanced Malignancies | Synovial Sarcoma | Renal Medullary Carcinoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Non-Hodgkin Lymphoma (NHL) | All Malignancies | Epithelioid Sarcoma (ES)

Spain, United States
Pfizer

Completed

CP-690,550 and Midazolam Drug-Drug Interaction Study

Healthy Volunteer

United States
LigaChem Biosciences, Inc.

Active, not recruiting

Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex

Mycobacterium Abscessus Infection | Nontuberculous Mycobacterium Infection

Korea, Republic of
Pfizer

Completed

A Midazolam Drug Interaction Study With PF-04171327

Healthy Volunteers

United States
Pfizer

Completed

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

Healthy Volunteers

United States
Takeda

Completed

TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin

Healthy Volunteers
Bayer

Completed

Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan

Endometriosis

Germany
The Third Affiliated Hospital of Guangzhou Medical...

Unknown

The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized and Cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction

Cerebral Infarction | Clopidogrel,Poor Metabolism of (Disorder)
University of Washington

Unknown

Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

Substance-Related Disorders

United States
Robert Bosch Gesellschaft für Medizinische Forschung...

Completed

Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene

Anovulation | Cytochrome P450 CYP3A Enzyme Deficiency | Disorder Due Cytochrome P450 CYP2D6 Variant

Germany
Northwestern University
Purdue University

Completed

Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum (CAMCAP)

Pregnancy Related

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers

Healthy | Pharmacokinetics | Drug Interactions
Pfizer

Completed

Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels

Healthy Volunteers

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Maryland Technology Development Corporation

Terminated

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Prostate Cancer

United States
National Science Centre, Poland
Medical University of Warsaw

Recruiting

The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma (FreeTAC)

Kidney Transplant Rejection | Liver Transplant; Complications | Immunosuppression | Metabolism Medication Toxicity | Genetic Predisposition | Kidney Transplant; Complications | Liver Transplant Rejection

Poland
The Third Xiangya Hospital of Central South University

Unknown

Clinical Study on the Effect of PTH on CYP3A4 Activity

Chronic Kidney Diseases

China
Astex Pharmaceuticals, Inc.

Completed

A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam

Healthy Volunteer

United States
Indivior Inc.
National Institute on Drug Abuse (NIDA)

Completed

Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults

Healthy

United States
Basilea Pharmaceutica

Completed

A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001

Fungal Infection

Netherlands
Galmed Pharmaceuticals Ltd
Hammersmith Medicines Research; Diamond Pharma Services Regulatory Affairs... and other collaborators

Completed

Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers

Healthy

United Kingdom
Astellas Pharma Inc

Completed

Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers

Pharmacokinetics of YM178

United States
AstraZeneca

Completed

Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2) (CYP)

Healthy

United Kingdom
Bayer

Completed

Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants

Drug Interactions

Germany
Boehringer Ingelheim

Completed

Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers

Healthy

Korea, Republic of
All India Institute of Medical Sciences, New Delhi
University of Zurich

Completed

Protocol for Correlating Enteropathic Severity and Small Intestinal CYP3A4 Activity in Patients With Celiac Disease (Cyp)

Celiac Disease

India
MODAG GmbH
Teva Pharmaceutical Industries, Ltd.; Quotient Sciences; Aptuit

Completed

A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)

Healthy Volunteers

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)

Chronic Obstructive Pulmonary Disease

Belgium
University Hospital Inselspital, Berne
Bayer

Completed

Rivaroxaban Hypericum Trial

Drug Interaction Study

Switzerland
H. Lundbeck A/S

Completed

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants

Healthy

Belgium
Insmed Incorporated

Completed

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Healthy Volunteers

United States
Bayer
Orion Corporation, Orion Pharma

Completed

Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction

Biological Availability

Germany
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

Multiple Myeloma | Non-Hodgkin's Lymphoma

Israel, Italy, Poland, South Africa, United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects

Cardiovascular Disease

United Kingdom
Assembly Biosciences

Completed

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

Chronic Hepatitis B

United States
Daiichi Sankyo, Inc.

Completed

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Drug Interaction Potential

United States, New Zealand, Taiwan, Netherlands
GlaxoSmithKline

Suspended

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years

Urinary Tract Infections

United Kingdom
GlaxoSmithKline

Completed

15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.

Sleep Initiation and Maintenance Disorders

Germany
Boehringer Ingelheim

Completed

Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Healthy
AstraZeneca

Completed

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate (AZD3293DDI)

Healthy Volunteers | Pharmacologic Action

United States
Yonsei University
Inje University

Completed

Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

Breast Neoplasms | Antineoplastic Agents | Therapeutic Uses | Survival Analysis

Korea, Republic of
GlaxoSmithKline

Completed

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

Nausea and Vomiting, Chemotherapy-Induced

United States
National Taiwan University Hospital

Unknown

The Influence of ABCB1、CYP3A4、CYP3A5、POR Genetic Polymorphism and Other Factors on Tacrolimus Blood Concentration

Liver Transplantation | Kidney Transplantation

Taiwan
Peking University People's Hospital
Yichang Humanwell Pharmaceutical Co., Ltd., China

Unknown

Impact of CYP3A4*1G Polymorphism on Non-analgesic Effects of Fentanyl in Chinese Han Patients

Fentanyl

China
St. Antonius Hospital

Completed

CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug (MEMO)

Morbid Obesity

Netherlands
Gerd Mikus

Completed

Influence of CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Bosentan

Drug Interactions

Germany
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

Healthy Volunteers

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

Advanced Solid Tumors, Excluding Breast Cancer

United States
Concert Pharmaceuticals

Completed

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

Health Volunteers

United States

3

Subscribe